טוען...
Mammalian target of rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late?
BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors have been shown to reduce the risk of tumour recurrence after liver transplantation for hepatocellular carcinoma (HCC). However, their role in established post-transplant HCC recurrence is uncertain. AIM: To investigate whether mTOR inhibit...
שמור ב:
| הוצא לאור ב: | World J Gastrointest Surg |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Baishideng Publishing Group Inc
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7215969/ https://ncbi.nlm.nih.gov/pubmed/32426094 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4240/wjgs.v12.i4.149 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|